A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma
Lili Mao, Jun Guo, Lingjun Zhu, Yu Jiang, Wangjun Yan, Jian Zhang, Ai‐Min Hui, Yuchen Yang, Lei Diao, Yan Tan, Han Zhao, Yiqian Jiang, Zhuli Wu, Lu Si
Topics & Concepts
Neuroblastoma RAS viral oncogene homologMutantMelanomaMedicineCancer researchOncologyInternal medicineChemistryCancerKRASGeneBiochemistryColorectal cancerMelanoma and MAPK PathwaysCutaneous Melanoma Detection and ManagementFOXO transcription factor regulation